基于卫生经济学评价的我国前列腺癌筛查项目策略优化研究  

Research on Optimizing Chinese Prostate Cancer Screening Project Based on Health Economics Evaluation

作　　者：秦晓健 顾成元[1,2] 黄永强 顾伟杰[1,2] 戴波 张海梁 朱耀[1,2] 刘天怡 刘一弘[3] 杨涵 曲姝丽[4] 叶定伟 QIN Xiao-jian;GU Cheng-yuan;HUANG Yong-qiang(Department of Urology,Fudan University Shanghai Cancer Center;Department of Oncology,Shanghai Medical College,Fudan University,Shanghai,200032,China;不详)

机构地区：[1]复旦大学附属肿瘤医院泌尿外科,上海200032 [2]复旦大学上海医学院肿瘤学系,上海200032 [3]阿斯利康投资(中国)有限公司医学事务部,上海201203 [4]艾昆纬企业管理咨询(上海)有限公司北京分公司,北京100006

出　　处：《中国卫生经济》2021年第6期9-13,共5页Chinese Health Economics

基　　金：上海市卫生健康委员会项目(2018ZHYL0201);上海市卫生健康委员会项目(2019SY074);上海市科学技术委员会项目(18511108000)。

摘　　要：目的:对男性采用PSA筛查前列腺癌的效果开展卫生经济学分析。方法:通过构建决策树-马尔可夫模型,分别从分年龄段,是否重复筛查和全社会视角下的成本收益3个角度,对前列腺癌筛查进行成本效果分析。结果:在50~65岁和65~80岁中,筛查组相比非筛查组的ICER分别为7 844.39元/QALY和9 961.87元/QALY;全年龄段重复筛查和不重复筛查策略下的ICER分别为9425.48元/QALY和21 078.00元/QALY;在全社会视角下,3个年龄组(50~65、65~80和50~80岁)的成本效益比分别为2.01,-0.51和1.00。结论:更早对我国男性进行前列腺癌的重复筛查是更具有成本效果优势的筛查策略。Objective:To conduct the health economics analysis of prostate-specific antigen-based screening for prostate cancer.Methods:Constructing a decision-tree Markov Model to explore the cost-effectiveness of screening strategies from the perspective of age group,whether is repeating screening and the societal perspective.Results:The ICER was 7844.39 CVY/QALY in the 50~65 years old age group and 9961.87 CNY/QALY in 65~80 years old age group respectively.The ICER was 9425.48 CNY/QALY and21078.00 CNY/QALY,in the repeating screening and non-repeating screening respectively;and the cost-benefit ratios were2.1,-0.51 and 1.00 in the 50~65 years old,65~80 years old and 50~80 years old age group respectively.Conclusion:It was more cost-effective to repeated screening in males earlier.

关 键 词：前列腺癌 筛查 成本-效果分析 

分 类 号：R1-9[医药卫生—公共卫生与预防医学] F019.6[经济管理—政治经济学]